HUP9903948A2 - Tachikinin antagonista 1-(1,2-diszubsztituált piperidinil)-4-(kondenzált imidazolil)-piperidin-származékok, előállításuk és alkalmazásuk - Google Patents

Tachikinin antagonista 1-(1,2-diszubsztituált piperidinil)-4-(kondenzált imidazolil)-piperidin-származékok, előállításuk és alkalmazásuk

Info

Publication number
HUP9903948A2
HUP9903948A2 HU9903948A HUP9903948A HUP9903948A2 HU P9903948 A2 HUP9903948 A2 HU P9903948A2 HU 9903948 A HU9903948 A HU 9903948A HU P9903948 A HUP9903948 A HU P9903948A HU P9903948 A2 HUP9903948 A2 HU P9903948A2
Authority
HU
Hungary
Prior art keywords
alkyl
pipe powder
tachikinin
antagonists
preparation
Prior art date
Application number
HU9903948A
Other languages
English (en)
Inventor
Frans Eduard Janssens
Joseph Elisabeth Leenaerts
Yves Emiel Maria Van Roosbroeck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP9903948A2 publication Critical patent/HUP9903948A2/hu
Publication of HUP9903948A3 publication Critical patent/HUP9903948A3/hu
Publication of HU229766B1 publication Critical patent/HU229766B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A cím szerinti vegyületek (I) általánős képletében n értéke 0, 1 vagy, m értéke 1 vagy 2, azzal a megkötésel, hőgy ha m értéke 2, akkőr nértéke 1, =Q jelentése =Q vagy =NR3, X jelentése kővalens kötés, -O-, -S- vagy -NR3-, R1 jelentése Ar1-, Ar1-(1-6 szénatőmős alkil)- vagy di(Ar1)-(1-6szénatőmős alkil)-csőpőrt, ahől az 1-6 szénatőmős alkilcsőpőrtők adőttesetben szűbsztitűálva lehetnek, R2 jelentése Ar2-, Ar2-(1-6 szénatőmős alkil)-, Het- vagy Het-(1-6szénatőmős alkil)-csőpőrt, R3 jelentése hidrőgénatőm vagy 1-6 szénatőmős alkilcsőpőrt, L jelentése (a-1) vagy (a-2) általánős képletű csőpőrt, és Ar1 jelentése adőtt esetben szűbsztitűált fenilcsőpőrt, Ar2 jelentése naftilcsőpőrt vagy adőtt esetben szűbsztitűáltfenilcsőpőrt, és Het jelentése adőtt esetben szűbsztitűált, egy- vagy kétgyűrűsheterőciklűsős csőpőrt. A vegyületek közelebbről gyógyszerkészítményeknem peptid jellegű P-anyag antagőnista hatóanyagaként alkalmazhatók. ŕ
HU9903948 1995-12-27 1996-12-20 1-(1,2-diszubsztituált piperidinil)-4-(kondenzált imidazolil)-piperidin-származékok HU229766B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203652 1995-12-27
PCT/EP1996/005885 WO1997024356A1 (en) 1995-12-27 1996-12-20 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives

Publications (3)

Publication Number Publication Date
HUP9903948A2 true HUP9903948A2 (hu) 2000-03-28
HUP9903948A3 HUP9903948A3 (hu) 2000-04-28
HU229766B1 HU229766B1 (hu) 2014-06-30

Family

ID=8221024

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903948 HU229766B1 (hu) 1995-12-27 1996-12-20 1-(1,2-diszubsztituált piperidinil)-4-(kondenzált imidazolil)-piperidin-származékok

Country Status (30)

Country Link
US (1) US6251894B1 (hu)
EP (1) EP0843679B1 (hu)
JP (1) JP4097043B2 (hu)
KR (1) KR100485147B1 (hu)
CN (1) CN1066733C (hu)
AR (2) AR005278A1 (hu)
AT (1) ATE208392T1 (hu)
AU (1) AU716071B2 (hu)
BR (1) BR9612307A (hu)
CA (1) CA2238817C (hu)
CY (1) CY2271B1 (hu)
CZ (1) CZ295861B6 (hu)
DE (1) DE69616802T2 (hu)
DK (1) DK0843679T3 (hu)
EA (1) EA001374B1 (hu)
ES (1) ES2167619T3 (hu)
HK (1) HK1011206A1 (hu)
HU (1) HU229766B1 (hu)
IL (2) IL124642A (hu)
MY (1) MY117680A (hu)
NO (1) NO310916B1 (hu)
NZ (1) NZ325845A (hu)
PL (1) PL183767B1 (hu)
PT (1) PT843679E (hu)
SI (1) SI0843679T1 (hu)
SK (1) SK283540B6 (hu)
TR (1) TR199801210T2 (hu)
TW (1) TW382017B (hu)
WO (1) WO1997024356A1 (hu)
ZA (1) ZA9610889B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527186B (en) 1996-03-19 2003-04-11 Janssen Pharmaceutica Nv Fused imidazole derivatives as multidrug resistance modulators
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
SI1144411T1 (en) * 1998-12-19 2005-10-31 Janssen Pharmaceutica N.V. Antihistaminic spiro compounds
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
EP1401838B1 (en) 2001-06-12 2014-03-26 Janssen Pharmaceutica NV Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
CN100379744C (zh) * 2001-11-23 2008-04-09 詹森药业有限公司 抗组胺药快速降低高颅内压的用途
AU2002354104A1 (en) 2001-12-10 2003-06-23 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
RU2301806C2 (ru) * 2002-01-16 2007-06-27 Янссен Фармацевтика Н.В. Прукалоприд-n-оксид
EP1473295B1 (en) * 2002-01-18 2009-04-01 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyrimidine derivatives
US7026309B2 (en) 2002-03-26 2006-04-11 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
ES2310260T3 (es) * 2002-12-23 2009-01-01 Janssen Pharmaceutica Nv Derivados sustituidos de 4-(4-piperidin-4-il-piperazin-1-il)-azepan y su uso como antagonistas de la neuroquinina.
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
BRPI0608074A2 (pt) 2005-03-03 2009-11-03 Janssen Pharmaceutica Nv derivados de oxa-diaza-espiro-[5.5]-undecanona substituìdos e uso como antagonistas da neurocinina do mesmo
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
EP0552292B1 (en) * 1990-10-10 1995-06-21 Schering Corporation Substituted imidazobenzazepines and imidazopyridoazepines
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition
IL101850A (en) * 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
CN1042228C (zh) * 1993-07-13 1999-02-24 詹森药业有限公司 抗过敏咪唑并吖庚因
CA2171850A1 (en) 1994-07-15 1996-02-01 Kiyoaki Katano Novel compound having platelet aggregation inhibitor effect
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
EA001374B1 (ru) 2001-02-26
DK0843679T3 (da) 2002-02-25
HUP9903948A3 (hu) 2000-04-28
IL124641A (en) 2001-11-25
NO982405L (no) 1998-08-19
DE69616802T2 (de) 2002-07-04
CZ295861B6 (cs) 2005-11-16
CN1206417A (zh) 1999-01-27
US6251894B1 (en) 2001-06-26
AR005278A1 (es) 1999-04-28
EP0843679B1 (en) 2001-11-07
DE69616802D1 (de) 2001-12-13
CA2238817C (en) 2006-10-17
EP0843679A1 (en) 1998-05-27
AU1308697A (en) 1997-07-28
PL327136A1 (en) 1998-11-23
AU716071B2 (en) 2000-02-17
ES2167619T3 (es) 2002-05-16
CZ186598A3 (cs) 1998-11-11
MY117680A (en) 2004-07-31
JP2000506503A (ja) 2000-05-30
ZA9610889B (en) 1998-06-23
PL183767B1 (pl) 2002-07-31
IL124642A0 (en) 1998-12-06
TW382017B (en) 2000-02-11
IL124642A (en) 2002-08-14
KR19990076715A (ko) 1999-10-15
HK1011206A1 (en) 1999-07-09
ATE208392T1 (de) 2001-11-15
CA2238817A1 (en) 1997-07-10
JP4097043B2 (ja) 2008-06-04
CY2271B1 (en) 2003-07-04
SK283540B6 (sk) 2003-09-11
NZ325845A (en) 1999-06-29
AR051817A2 (es) 2007-02-14
SK83098A3 (en) 1999-01-11
TR199801210T2 (xx) 1999-10-21
KR100485147B1 (ko) 2005-09-13
BR9612307A (pt) 1999-07-13
NO982405D0 (no) 1998-05-27
PT843679E (pt) 2002-04-29
SI0843679T1 (en) 2002-06-30
NO310916B1 (no) 2001-09-17
EA199800603A1 (ru) 1998-12-24
IL124641A0 (en) 1998-12-06
HU229766B1 (hu) 2014-06-30
WO1997024356A1 (en) 1997-07-10
CN1066733C (zh) 2001-06-06

Similar Documents

Publication Publication Date Title
HUP9903948A2 (hu) Tachikinin antagonista 1-(1,2-diszubsztituált piperidinil)-4-(kondenzált imidazolil)-piperidin-származékok, előállításuk és alkalmazásuk
HUP0000562A2 (hu) Kondenzált pirazolszármazékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények
WO2001038324A3 (en) Imidazole derivatives and their use as raf kinase inhibitors
HUP0303339A2 (hu) Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
HUP9901820A2 (hu) 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
HUP0103413A2 (hu) Heterociklusos származékok mint rotamáz-enzimek inhibitorai, köztitermékei, eljárás ezek előállítására, és ezeket tartalmazó gyógyszerkészítmények
HUP0003355A2 (hu) Tieno[2,3-d]pirimidindion-származékok és ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
MY117557A (en) 1-(1,2-disubstituted piperidinyl)-4- substituted piperidine derivatives
ATE472537T1 (de) 2,4-di(hetero-)arylamino(-oxy)-5-substituierte pyrimidinderivate als antineoplastika
CO5540306A2 (es) Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
HUP0102453A2 (hu) Adenozinszármazékok, alkalmazásuk és e vegyületeket tartalmazó gyógyászati készítmények
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
MX9305027A (es) 4- 2-(4-(2-piridiniloxi)fenil)etoxi] quinazolina yanalogos de la misma.
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
NO324229B1 (no) 2-hydroksymutilinkarbamat-derivater, anvendelse derav, farmasoytisk sammensetning samt fremgangsmate for fremstilling av en slik forbindelse
HUP9903590A2 (hu) 3-(Azetidinil-alkil)-piperidin- vagy -pirrolidin-származékok mint tachikinin-antagonisták
MY121580A (en) 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl-and imidazopyridinyl)- piperidine derivatives
HUP0303038A2 (hu) Szubsztituált azolszármazékok mint kortikotropin releasing faktor inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9801950A2 (hu) 2-(Aril-fenil-amino)-imidazolin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE69109090D1 (de) 2-substituierte 4,5-diphenylimidazole.
HUP0101469A2 (hu) 5-[(2-Imidazolidinilidén)-amino]-benzimidazol-származékok, előállításuk és alkalmazásuk javított metabolikus stabilitású alfa-adrenoceptor agonistákként
NO972938L (no) Farmasöytiske piperazinforbindelser
HUP9701921A2 (hu) Heterociklusos amino-metil-vegyületek, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees